Global burden of human papillomavirus and related diseases.

By David Forman, Catherine de Martel, C. Lacey, Isabelle Soerjomataram, J. Lortet-Tieulent, L. Bruni, J. Vignat, J. Ferlay, F. Bray, Martyn Plummer and 1 more. Vaccine, 2012

1,666 citations recorded by the source corpus.

Subfields: Epidemiology, Oncology, Surgery

View Paper: https://www.semanticscholar.org/paper/8dbb97ca8fa51d4a5530e6125f26562c48109486

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. A. Jemal
2. R. Siegel
3. F. Bray
4. J. Ferlay

In Oncology

1. R. Siegel
2. A. Jemal
3. J. Ferlay
4. F. Bray
5. Lindsey A. Torre
6. J. Lortet-Tieulent
7. Isabelle Soerjomataram
8. Prashanth Rawla

In Surgery

1. A. Jemal
2. J. Ferlay
3. F. Bray
4. R. Siegel

Citations in the corpus

• Evidence for single-dose protection by the bivalent HPV vaccine—review of the Costa Rica HPV Vaccine Trial and future research studies (2018, background): “If current trends go unabated, the absolute number of cases is expected to increase due to population growth and aging [2], yet, tools to interrupt this trajectory are available.”
• US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. (2015, background): “HPV detection varies from 40% in vaginal to 90% in anal cancers (2).”
• Global cancer statistics, 2012 (2015, background): “Most affected are younger women in several countries, including many in Europe, Central Asia, Japan, and China(91,95); this cohort-driven trend is thought to reflect increases in high-risk HPV prevalence from changing sexual behaviors.(93) There are 2 vaccines (Gardasil [Merck and Company, Whitehous”